Glenmark Launches Global Phase 3 Trial for Novel Lung Cancer Treatment Envafolimab
AI-Generated Summary
Glenmark Pharmaceuticals has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, targeting resectable Stage III Non-Small Cell Lung Cancer (NSCLC). The study will assess the drug's efficacy and safety, with patient enrollment commencing in India and planned for Russia, Brazil, and Mexico. Envafolimab, already approved in China for other indications, offers subcutaneous administration which could enhance accessibility and convenience for patients. This global effort aims to address the urgent need for innovative immunotherapy options in this aggressive form of lung cancer.
In a nutshell
This pivotal trial addresses a critical unmet need for more accessible and effective immunotherapy options in Stage III NSCLC, a stage associated with poor five-year survival rates despite surgical intervention. The subcutaneous administration of Envafolimab could significantly improve patient convenience and reduce healthcare burdens, particularly benefiting regions with limited resources.
Source: PR Newswire UK
